U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323524) titled 'Dapagliflozin in Active Lupus Nephritis' on Jan. 05.
Brief Summary: Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Study Start D...